

# Edith A Nutescu

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3665031/edith-a-nutescu-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141  
papers

3,391  
citations

31  
h-index

54  
g-index

149  
ext. papers

3,826  
ext. citations

3.7  
avg. IF

5.19  
L-index

#	Paper	IF	Citations
141	Association between transportation barriers and anticoagulation control among an inner-city, low-income population: A prospective observational cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12605	5.1	1
140	Can clinical pharmacists utilize telehealth to double the safety and efficacy of oral anticoagulation while reducing health care costs and improving patient satisfaction in patients with atrial fibrillation?. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2021</b> , 4, 969-977	1.4	
139	Type 2 diabetes mellitus burdens among adults with sickle cell disease: A 12-year single health system-based cohort analysis. <i>EJHaem</i> , <b>2021</b> , 2, 97-101	0.9	
138	Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Adults in the United States, 2011-2016. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e006215	5.8	9
137	Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	
136	Why African Americans say "No": A Study of Pharmacogenomic Research Participation. <i>Ethnicity and Disease</i> , <b>2020</b> , 30, 159-166	1.8	3
135	Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey. <i>Journal of Diabetes</i> , <b>2020</b> , 12, 385-395	3.8	5
134	Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis. <i>Journal of Cancer Survivorship</i> , <b>2020</b> , 14, 294-304	5.1	5
133	Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 67-75	1.9	5
132	Immigration Status and Disparities in the Treatment of Cardiovascular Disease Risk Factors in the Hispanic Community Health Study/Study of Latinos (Visit 2, 2014-2017). <i>American Journal of Public Health</i> , <b>2020</b> , 110, 1397-1404	5.1	5
131	The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. <i>Clinical and Translational Science</i> , <b>2019</b> , 12, 209-217	4.9	17
130	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 55-66	5.8	4
129	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 1077-1089	6.2	9
128	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 116-127	4.5	9
127	Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 921-928	5.8	2
126	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner et al. <i>British Journal of Haematology</i> , <b>2019</b> , 186, 782-783	4.5	
125	Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population. <i>Pharmacotherapy</i> , <b>2018</b> , 38, 205-216	5.8	14

124	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 181-191	5	156
123	Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas. <i>Blood</i> , <b>2018</b> , 132, 2280-2280	2.2	0
122	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 4693-4693	2.2	
121	Outcomes of systematic anticoagulation management in pharmacist and nurse specialized clinics. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2018</b> , 1, 68-73	1.4	1
120	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 259-270	4.5	12
119	A New Approach towards Minimizing the Risk of Mis dosing Warfarin Initiation Doses. <i>Computational and Mathematical Methods in Medicine</i> , <b>2018</b> , 2018, 5340845	2.8	4
118	Correlations between the enantio- and regio-selective metabolisms of warfarin. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 133-142	2.6	
117	High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 435-441	5.1	14
116	Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. <i>Pharmacotherapy</i> , <b>2017</b> , 37, 1221-1230	5.8	60
115	Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review. <i>Annals of Pharmacotherapy</i> , <b>2017</b> , 51, 1122-1137	2.9	42
114	Implementation of inpatient models of pharmacogenetics programs. <i>American Journal of Health-System Pharmacy</i> , <b>2016</b> , 73, 1944-1954	2.2	23
113	Upper-Extremity Deep-Vein Thrombosis: A Retrospective Cohort Evaluation of Thrombotic Risk Factors at a University Teaching Hospital Antithrombosis Clinic. <i>Annals of Pharmacotherapy</i> , <b>2016</b> , 50, 637-44	2.9	6
112	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 15-31	5.1	66
111	Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 217-25	2.6	11
110	Integrating electronic health records in the delivery of optimized anticoagulation therapy. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 125-6	2.9	
109	Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 439-47	2.5	13
108	Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 73-81	1.9	61
107	Practical management of anticoagulation in patients with atrial fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1340-1360	15.1	67

106	Relationship between time spent at extreme International Normalized Ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients. <i>American Journal of Health-System Pharmacy</i> , <b>2015</b> , 72, 1188-94	2.2	9
105	Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy. <i>Journal of Medical Economics</i> , <b>2015</b> , 18, 1041-9	2.4	2
104	Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. <i>Thrombosis Research</i> , <b>2015</b> , 135, 303-10	8.2	42
103	Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. <i>Journal of Medical Economics</i> , <b>2014</b> , 17, 52-64	2.4	56
102	Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice. <i>Thrombosis Research</i> , <b>2014</b> , 134, 807-13	8.2	12
101	Balance of academic responsibilities of clinical track pharmacy faculty in the United States: a survey of select American College of Clinical Pharmacy Practice and Research Network Members. <i>Pharmacotherapy</i> , <b>2014</b> , 34, 1239-49	5.8	12
100	Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism. <i>Thrombosis Research</i> , <b>2014</b> , 133, 743-9	8.2	16
99	Feasibility of implementing a comprehensive warfarin pharmacogenetics service. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 1156-64	5.8	57
98	Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. <i>American Journal of Health-System Pharmacy</i> , <b>2013</b> , 70, 1914-29	2.2	47
97	Incidence of venous thromboembolism in nursing home residents. <i>Journal of the American Medical Directors Association</i> , <b>2013</b> , 14, 578-84	5.9	14
96	Rivaroxaban: practical considerations for ensuring safety and efficacy. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 1223-48	5.8	11
95	Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 714-24	2.9	34
94	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. <i>Lancet, The</i> , <b>2013</b> , 382, 790-6	4.0	191
93	Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 525-34	4	2
92	Personalized medicine in cardiology: the time for genotype-guided therapy is now. <i>Future Cardiology</i> , <b>2013</b> , 9, 459-64	1.3	1
91	Warfarin anticoagulation after total hip or total knee replacement: clinical and resource-utilization outcomes in a university-based antithrombosis clinic. <i>American Journal of Health-System Pharmacy</i> , <b>2013</b> , 70, 423-30	2.2	6
90	Oral anticoagulant therapies: balancing the risks. <i>American Journal of Health-System Pharmacy</i> , <b>2013</b> , 70, S3-11	2.2	30
89	All-cause and disease-related health care costs associated with recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 1288-97	7	17

88	Apixaban: a novel oral inhibitor of factor Xa. <i>American Journal of Health-System Pharmacy</i> , <b>2012</b> , 69, 1113-26	24
87	Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home. <i>American Journal of Geriatric Pharmacotherapy</i> , <b>2012</b> , 10, 361-72	8
86	All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. <i>Journal of Managed Care Pharmacy</i> , <b>2012</b> , 18, 363-74	35
85	A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery. <i>Current Orthopaedic Practice</i> , <b>2012</b> , 23, 221-228	0.4 1
84	Association of the GGCC (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. <i>Pharmacogenetics and Genomics</i> , <b>2012</b> , 22, 152-8	1.9 30
83	Pharmacogenomics of warfarin dose requirements in Hispanics. <i>Blood Cells, Molecules, and Diseases</i> , <b>2011</b> , 46, 147-50	2.1 34
82	Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption. <i>Pharmacotherapy</i> , <b>2011</b> , 31, 1161-74	5.8 17
81	Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. <i>Pharmacotherapy</i> , <b>2011</b> , 31, 1232-49	5.8 25
80	Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. <i>Pharmacotherapy</i> , <b>2011</b> , 31, 785-92	5.8 16
79	Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 425-42	3.5 7
78	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 326-43	5.1 173
77	Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism. <i>Current Medical Research and Opinion</i> , <b>2011</b> , 27, 1973-85	2.5 9
76	Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. <i>Journal of Medical Economics</i> , <b>2011</b> , 14, 324-34	2.4 14
75	Anticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures. <i>American Journal of Health-System Pharmacy</i> , <b>2011</b> , 68, 1239-44	2.2 13
74	Characteristics of novel anticoagulants and potential economic implications. <i>American Journal of Managed Care</i> , <b>2011</b> , 17, S27-32	2.1 7
73	Dosing guidelines, not protocols, for managing warfarin therapy. <i>American Journal of Health-System Pharmacy</i> , <b>2010</b> , 67, 1554-6	2.2 7
72	A clinician@ guide to perioperative bridging for patients on oral anticoagulation. <i>Journal of Pharmacy Practice</i> , <b>2010</b> , 23, 303-12	1.3 6
71	Thrombotic risk and immobility in residents of long-term care facilities. <i>Journal of the American Medical Directors Association</i> , <b>2010</b> , 11, 211-21	5.9 19

70	Effects of clinical decision support on venous thromboembolism risk assessment, prophylaxis, and prevention at a university teaching hospital. <i>American Journal of Health-System Pharmacy</i> , <b>2010</b> , 67, 1265-73	2.2	34
69	Anticoagulation management services: entering a new era. <i>Pharmacotherapy</i> , <b>2010</b> , 30, 327-9	5.8	12
68	Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 1165-72	2.9	17
67	Predictors of unstable anticoagulation in African Americans. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 27, 430-7	5.1	20
66	Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke. <i>Cerebrovascular Diseases</i> , <b>2009</b> , 27, 585-93	3.2	3
65	Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 1064-83	2.9	207
64	Warfarin INR Patterns Following Total Hip Arthroplasty.. <i>Blood</i> , <b>2009</b> , 114, 1068-1068	2.2	
63	Warfarin INR Patterns Following Total Knee Arthroplasty.. <i>Blood</i> , <b>2009</b> , 114, 2100-2100	2.2	
62	New anticoagulant agents: direct thrombin inhibitors. <i>Cardiology Clinics</i> , <b>2008</b> , 26, 169-87, v-vi	2.5	43
61	Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. <i>Annals of Pharmacotherapy</i> , <b>2008</b> , 42, 979-88	2.9	75
60	Rivaroxaban: an oral direct inhibitor of factor Xa. <i>American Journal of Health-System Pharmacy</i> , <b>2008</b> , 65, 1520-9	2.2	58
59	Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery. <i>Annals of Pharmacotherapy</i> , <b>2008</b> , 42, 1216-21	2.9	15
58	Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 95-105	4	3
57	Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 26, 248-50	5.1	6
56	Quality of Oral Anticoagulation Management in Pharmacist Vs Nurse Managed Models of Care. <i>Blood</i> , <b>2008</b> , 112, 4665-4665	2.2	
55	Differences among Various Low-Molecular-Weight Heparins in Patients with Severe Renal Insufficiency: An Analysis of Recent Clinical Trials. <i>Blood</i> , <b>2008</b> , 112, 4047-4047	2.2	
54	Basic terminology in obtaining reimbursement for pharmacists' cognitive services. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, 186-92	2.2	12
53	ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, 2281-91	2.2	3

52	Assessing, preventing, and treating venous thromboembolism: evidence-based approaches. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, S5-13	2.2	34
51	Survey of hospitals for guidelines, policies, and protocols for anticoagulants. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, 1203-8	2.2	19
50	Factors influencing warfarin dose requirements in African-Americans. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 1535-46	4.6	67
49	Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. <i>Chest</i> , <b>2006</b> , 130, 1385-9	5.3	52
48	Sex difference in the antiplatelet effect of aspirin in patients with stroke. <i>Annals of Pharmacotherapy</i> , <b>2006</b> , 40, 812-7	2.9	23
47	Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach. <i>Annals of Pharmacotherapy</i> , <b>2006</b> , 40, 1558-71	2.9	7
46	Warfarin and its interactions with foods, herbs and other dietary supplements. <i>Expert Opinion on Drug Safety</i> , <b>2006</b> , 5, 433-51	4.1	104
45	New anticoagulant agents: direct thrombin inhibitors. <i>Clinics in Geriatric Medicine</i> , <b>2006</b> , 22, 33-56, viii	3.8	10
44	Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 101-10	1.9	285
43	Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. <i>Value in Health</i> , <b>2006</b> , 9, 68-76	3.3	16
42	Quality of Warfarin Management in Anticoagulation Clinics in the U.S.. <i>Blood</i> , <b>2006</b> , 108, 627-627	2.2	1
41	Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 96, 137-41	7	6
40	Drug evaluation: the directly activated Factor Xa inhibitor otamixaban. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2006</b> , 9, 854-65		1
39	Anticoagulant agents are mainstay therapies in the prevention and treatment of arterial and venous thrombosis. Introduction. <i>American Journal of Managed Care</i> , <b>2006</b> , 12, S427-9	2.1	
38	Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapies. <i>American Journal of Managed Care</i> , <b>2006</b> , 12, S444-50	2.1	1
37	Economic considerations in managing patients with chronic stable angina. <i>Journal of Managed Care Pharmacy</i> , <b>2006</b> , 12, S17-21		
36	Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 1275-85	2.9	54
35	Factors that influence prescribing within a therapeutic drug class. <i>Journal of Evaluation in Clinical Practice</i> , <b>2005</b> , 11, 357-65	2.5	12

34	Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2005</b> , 7, 241-50	2.1	4
33	Current and emerging treatment options for venous thrombosis: a case discussion. <i>American Journal of Health-System Pharmacy</i> , <b>2005</b> , 62, 593-605	2.2	
32	Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 1049-55	2.9	11
31	A pharmacologic overview of current and emerging anticoagulants. <i>Cleveland Clinic Journal of Medicine</i> , <b>2005</b> , 72 Suppl 1, S2-6	2.8	45
30	Strategies for cost-effective prevention and treatment of venous thromboembolism. Introduction. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, S3-4	2.2	2
29	Emerging options in the treatment of venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, S12-7	2.2	5
28	Point of care monitors for oral anticoagulant therapy. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2004</b> , 30, 697-702	5.3	7
27	Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2004</b> , 30, 619-26	5.3	11
26	Direct thrombin inhibitors for anticoagulation. <i>Annals of Pharmacotherapy</i> , <b>2004</b> , 38, 99-109	2.9	44
25	Ximelagatran: an oral direct thrombin inhibitor. <i>Annals of Pharmacotherapy</i> , <b>2004</b> , 38, 1881-97	2.9	10
24	Factors that influence prescribing decisions. <i>Annals of Pharmacotherapy</i> , <b>2004</b> , 38, 557-62	2.9	74
23	Impact of prescribing guidelines for inpatient anticoagulation. <i>Annals of Pharmacotherapy</i> , <b>2004</b> , 38, 1570-5	2.9	10
22	Introduction Current Concepts in Thrombosis Management: Focus on Factor Xa Inhibition. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 61S-61S	5.8	
21	Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 82S-87S	5.8	2
20	Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 88S-94S	5.8	17
19	Treatment of venous thromboembolism: challenging the unfractionated heparin standard. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 127S-131S	5.8	2
18	Impact of oral direct thrombin inhibitors on anticoagulation clinics. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 1204-12	5.8	4
17	New Developments in Anticoagulation Therapy: Oral Direct Thrombin Inhibitors. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 165S-165S	5.8	



16	Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 199S-202S	5.8	10
15	Oral Anticoagulation: Preparing for Change. <i>Journal of the American Medical Directors Association</i> , <b>2004</b> , 5, 2-10	5.9	4
14	New blood thinner offers first potential alternative in 50 years: ximelagatran. <i>Journal of Cardiovascular Nursing</i> , <b>2004</b> , 19, 374-83	2.1	5
13	Oral anticoagulation: preparing for change. <i>Journal of the American Medical Directors Association</i> , <b>2004</b> , 5, 2-11	5.9	1
12	Tinzaparin: considerations for use in clinical practice. <i>Annals of Pharmacotherapy</i> , <b>2003</b> , 37, 1831-40	2.9	6
11	The future of anticoagulation clinics. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2003</b> , 16, 61-3	5.1	15
10	Ezetimibe: a selective cholesterol absorption inhibitor. <i>Pharmacotherapy</i> , <b>2003</b> , 23, 1463-74	5.8	61
9	Hospital guidelines for use of low-molecular-weight heparins. <i>Annals of Pharmacotherapy</i> , <b>2003</b> , 37, 1072-81	5.1	6
8	Wound Pharmacobiology. <i>Orthopedics</i> , <b>2003</b> , 26,	1.5	3
7	Wound pharmacobiology. <i>Orthopedics</i> , <b>2003</b> , 26, s837-42	1.5	1
6	Antithrombotic therapy for the treatment of venous thromboembolism. <i>American Journal of Managed Care</i> , <b>2003</b> , 9, S103-14; quiz S115-20	2.1	2
5	Survey of hospital policies regarding low-molecular-weight heparins. <i>American Journal of Health-System Pharmacy</i> , <b>2002</b> , 59, 534-8	2.2	11
4	Traditional versus modern anticoagulant strategies: summary of the literature. <i>American Journal of Health-System Pharmacy</i> , <b>2002</b> , 59, S7-14	2.2	10
3	Dosing and monitoring of low-molecular-weight heparins in special populations. <i>Pharmacotherapy</i> , <b>2001</b> , 21, 218-34	5.8	105
2	Warfarin-acetaminophen drug interaction revisited. <i>Pharmacotherapy</i> , <b>1999</b> , 19, 1153-8	5.8	20
1	Multidisciplinary approach to improving allergy documentation. <i>American Journal of Health-System Pharmacy</i> , <b>1998</b> , 55, 364-8	2.2	3